Pharmaceuticals NRx Pharmaceuticals Submits Two New Drug Applications for Depression Treatments NRX-101 and NRX-100 Last updated: July 1, 2024 5:54 pm By bexib 0 Min Read Share SHARE The company says that if both NRX-101 and NRX-100 are approved, it expects to generate revenue of more than $150 per NRXP share in the near future. You Might Also Like APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins New ways to determine drug value with health equity in mind Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer Share This Article Facebook Twitter Email Print Previous Article An inside look: Payments as a service Next Article Roaring Kitty sued over GameStop ‘pump and dump’ allegations – Investorempires.com Leave a comment Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. Stay ConnectedFacebookLikeTwitterFollowYoutubeSubscribeTelegramFollowLatest News Upskilling: An interview with Steph Piper Manufacturing Young Kiwis toast change: hazardous drinking falls by 13% in five years Hospitality & Tourism Clearview FCU saves 6,000 labor hours through RPA Banking Inside Varo Bank’s GEN AI Copilot build Banking